Ascletis Pharma Inc. (01672) published a Next Day Disclosure Return dated 17 October 2025, detailing revisions to its issued share capital and treasury share holdings. As of 15 October 2025, the company held 992,874,320 issued shares (excluding treasury shares) and 6,084,210 treasury shares, bringing the total to 998,958,530. On 17 October 2025, 100,000 shares were repurchased and placed into treasury at an average price of HKD 9.1525 per share, resulting in an aggregate payment of HKD 915,250. After this transaction, the number of issued shares (excluding treasury shares) was 992,774,320, with 6,184,210 treasury shares, maintaining the overall total of 998,958,530.

Data in the disclosure also shows multiple share repurchases for cancellation that have not yet been cancelled, conducted between 03 April 2025 and 13 October 2025, covering a total of 860,000 shares at prices ranging from HKD 4.8531 to HKD 11.1022. Under a repurchase mandate granted on 22 May 2025, Ascletis Pharma Inc. is authorized to repurchase 96,284,628 shares. To date, 560,000 shares have been repurchased on the market or another exchange under this mandate, representing approximately 0.0581% of the issued shares at the time the mandate was granted.

According to the filing, there is a moratorium on any new issue of shares or transfer of treasury shares until 16 November 2025, thereby aligning with the requirements of the repurchase mandate. The company states that all repurchases were executed in accordance with the applicable listing rules and its previously filed Explanatory Statement.